SCHEMBL23910649

SCHEMBL23910649

CC(C)(C)[Si](C)(C)OCCNc1cc(Br)ccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR7 P34969 3/20 0.35
LRRK2 Q5S007 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
HRH4 Q9H3N8 1/20 0.33
DRD2 P14416 1/20 0.32
ADRA1D P25100 1/20 0.32
HTR2C P28335 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
RIOK2 Q9BVS4 1/20 0.32
CYP1A2 P05177 5/20 0.31
CYP3A4 P08684 2/20 0.31
RAB9A P51151 1/20 0.31
DUT P33316 2/20 0.31
KDM4D Q6B0I6 2/20 0.31
CYP2C19 P33261 4/20 0.30
ALOX15 P16050 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26686762 0.79 LRRK2 (0.50) MEN1KMT2AHTR7LRRK2ALDH1A1
SCHEMBL15205661 0.79 ATM (0.43) MEN1KMT2AALDH1A1KDM4ERAB9A
SCHEMBL4035843 0.78 CYP2C19 (0.50) ALDH1A1KDM4EDRD2ADRA1ACYP1A2
SCHEMBL17614048 0.76 HTR7 (0.36) MEN1KMT2AHTR7LRRK2ALDH1A1
SCHEMBL4647621 0.75 CYP1A2 (0.38) HTR7ALDH1A1HRH4ADRA1DHTR2C
SCHEMBL2523541 0.75 ALDH1A1 (0.41) MEN1KMT2AALDH1A1KDM4ERAB9A
SCHEMBL22385034 0.75 RIOK2 (0.32) MEN1KMT2AALDH1A1KDM4ERIOK2
SCHEMBL2170006 0.74 CCNC (0.47) MEN1KMT2AALDH1A1KDM4EHRH4
SCHEMBL28978598 0.74 HTR7 (0.36) HTR7LRRK2ALDH1A1DRD2ADRA1D
SCHEMBL26686538 0.74 SMN1; SMN2 (0.44) MEN1KMT2AHTR7LRRK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115916778-A Methionine adenosyltransferase inhibitor, preparation method and application thereof 赛诺哈勃药业(成都)有限公司 2023-04-04 CN disclosed
WO-2022053022-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 赛诺哈勃药业(成都)有限公司 2022-03-17 WO disclosed
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF USP7, SENP7, USP8 MEN1 3693/4885KMT2A 2614/4885HTR7 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.